Filed with ASX · · 3 pages · English
CLEO Diagnostics Ltd has announced the commencement of its Analytical Validation program for its Pre-Surgical Ovarian Cancer Test, marking a significant step towards FDA submission. This program will evaluate the performance of three independently manufactured batches of test kits to ensure precision and robustness of the assay. The validation process is expected to take approximately three months and is a critical component of the company's regulatory pathway.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement Cleo Diagnostics Ltd ASX:COV Level 2, 480 Collins Street, Melbourne, VIC, 3000 ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com Directors Chair and Non-Executive Director Adrien Wing Chief Executive Officer and Executive Director Dr Richard Allman Chief Scientific...
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics